15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering RenovoRx Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $14.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.50 sits 787% above the current $0.96. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $-0.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to RenovoRx Inc.
As of Jul, 2 of 2 firms rate RNXT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RNXT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.08 – $-0.07 · 2 analysts · -6% YoY
Next period, 2 analysts expect RenovoRx Inc to earn $-0.07 a share (range $-0.08 – $-0.07), versus $-0.08 a year earlier. Full-year consensus is $-0.31, growing to $-0.15 the year after.
REVENUE · NEXT QUARTER
$811.5K
Range $550.0K – $974.0K · 2 analysts · +205% YoY
Revenue is expected to reach $811.5K (range $550.0K – $974.0K), +205.1% year-over-year. Full-year consensus is $3.2M, rising to $12.3M next year.
Top analysts covering RenovoRx Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RNXT.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$3.00+213.0% to target
Overall win rate
37%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #358
Buy
$14.00+1360.5% to target
Overall win rate
26%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #360
Buy
$4.00+317.3% to target
Overall win rate
30%
+ Follow
RNXT stock forecast FAQ
What is RNXT's average 12-month price target?+
The 2 analysts with a live target average $8.50 for RenovoRx Inc over the next 12 months, ranging from a $14.00 high to a $3.00 low.
Is RNXT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RNXT?+
The Street-high target is $14.00 (Ascendiant Capital), and the Street-low is $3.00 (HC Wainwright & Co.). The average of all 2 active targets is $8.50.
How many Wall Street analysts cover RNXT?+
2 analysts have an active rating on RenovoRx Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering RNXT?+
Among analysts who currently cover RNXT, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #230). Their current call is Buy with a $3.00 target.
What is RenovoRx Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.08 – $-0.07) across 2 analysts. Full-year EPS is projected at $-0.31, rising to $-0.15 the following year.
How much revenue is RenovoRx Inc expected to report next quarter?+
Consensus revenue is $811.5K (range $550.0K – $974.0K). Full-year revenue is projected at $3.2M, growing to $12.3M next year.
Have analysts been upgrading or downgrading RNXT lately?+
As of Jul, 2 of 2 firms rate RNXT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RNXT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
